FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activationRuiqi Zhu, Donald Small|Signal Transduction and Targeted Therapy|2021Cited by 106
Fatty acid distribution in systems modeling the normal and diabetic human circulation. A 13C nuclear magnetic resonance study.David P. Cistola, Donald Small|Journal of Clinical Investigation|1991Cited by 92
IMC-EB10, an Anti-FLT3 Monoclonal Antibody, Prolongs Survival and Reduces Nonobese Diabetic/Severe Combined Immunodeficient Engraftment of Some Acute Lymphoblastic Leukemia Cell Lines and Primary Leukemic SamplesObdulio Piloto, Donald Small|Cancer Research|2006Cited by 44
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitorsBao Nguyen, Donald Small|Oncotarget|2017Cited by 40
Targeting rapid <scp>TKI</scp> ‐induced <scp>AXL</scp> upregulation overcomes adaptive <scp>ERK</scp> reactivation and exerts antileukemic effects in <i>FLT3</i> / <scp>ITD</scp> acute myeloid leukemiaTessa Seale, Donald Small|Molecular Oncology|2024Cited by 3